Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Study of Cemiplimab With or Without RP1 in Cutaneous Squamous Cell Carcinoma
2018-003964-30Phase 2Active
- Sponsor
- Replimune Group, Inc.
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cutaneous squamous cell carcinoma (cSCC) comparing Cemiplimab monotherapy with Cemiplimab + RP1 combination (2 arms). Primary endpoint: Objective response rate by central review (overall population). Started Nov 2019; status: active.
02
Drugs
cemiplimabvusolimogene oderparepvec
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2018-003964-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003964-30.